Furthermore, although SNORD66 displayed increased expression in plasma of COPD patients as compared with that in plasma of the healthy controls, it had considerably higher plasma expression level in NSCLC patients compared with COPD individuals. This evidence concerns the gene SNORD66 and non-small cell lung carcinoma.